Citizens Financial Group Inc. RI Reduces Stake in Merck & Co., Inc. $MRK

Citizens Financial Group Inc. RI lowered its position in Merck & Co., Inc. (NYSE:MRK) by 2.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 261,913 shares of the company’s stock after selling 7,749 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Merck & Co., Inc. were worth $33,656,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Pinnbrook Capital Management LP increased its stake in shares of Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after buying an additional 11,355 shares during the period. Cibc World Market Inc. grew its holdings in Merck & Co., Inc. by 32.6% during the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after acquiring an additional 320,143 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Merck & Co., Inc. by 13.9% during the 4th quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after acquiring an additional 224,752 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Merck & Co., Inc. by 2.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock valued at $331,931,000 after purchasing an additional 51,393 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its holdings in shares of Merck & Co., Inc. by 410.5% in the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock valued at $74,255,000 after purchasing an additional 567,249 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 20,784 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last quarter. 0.17% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Analyst Upgrades and Downgrades

MRK has been the subject of several recent analyst reports. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. UBS Group upped their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Argus increased their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday. BMO Capital Markets raised their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, August 20th. Finally, Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a research note on Wednesday, August 12th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $147.60.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $153.21 on Thursday. The stock has a market capitalization of $378.00 billion, a PE ratio of 122.57, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $156.92. The stock’s 50-day moving average price is $130.39 and its 200 day moving average price is $122.04. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period last year, the firm earned $2.13 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.